Aiyar Ram
Known title: President and CEOCIK: 0001997920
Associated companies
Transaction History
| KRRO | ▼ Sell | Open Market | 5,802 | $63K | 8/4/2026 | View on chart |
| KRRO | ▼ Sell | Open Market | 15,152 | $197K | 5/29/2026 | View on chart |
| KRRO | ▲ Buy | Grant | 50,000 | $617K | 5/26/2026 | View on chart |
| KRRO | ▲ Buy | Grant | 40,000 | $0 | 2/2/2026 | View on chart |
| KRRO | ▲ Buy | Grant | 4,613 | — | 11/3/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Korro Bio Begins Phase 1/2 Trial for KRRO-121
Korrr Bio has begun dosing the first cohort of its Phase 1/2 study for KRRO-121, a therapy aimed at treating hyperammonemia in patients with urea cycle disorders. The initiation of this trial marks a significant milestone in the drug’s development timeline. Analysts continue to hold a $15 price target, reflecting confidence in the program. Current technical data shows the stock trading near its 52‑week low with an RSI of 39.7.
Korro Bio Begins Phase 1/2 Trial for KRRO-121. Korrr Bio has begun dosing the first cohort of its Phase 1/2 study for KRRO-121, a therapy aimed at treating hyperammonemia in patients with urea cycle disorders. The initiation of this trial marks a significant milestone in the drug’s development timeline. Analysts continue to hold a $15 price target, reflecting confidence in the program. Current technical data shows the stock trading near its 52‑week low with an RSI of 39.7.